How Cisplatin Came To Be Used As Treatment
Cisplatin, sometimes referred to as CDDP, is a platinum-based chemotherapy drug and is a member of a group of drugs known as alkylating agents. It was initially recognized as a compound by chemist M. Peyrone in 1845 and was known for many years as Peyrone’s salt. In 1893, chemist Alfred Werner completed his research and published his findings on the chemical structure of cisplatin.
After later research showed that cisplatin inhibited cell division in bacteria, Dr. Barnett Rosenberg, a Michigan State University professor of chemistry, recognized its potential as a treatment for mesothelioma. Following extensive research and development during the mid-70s, cisplatin was approved by the U.S. Food and Drug Administration (FDA) as an anticancer drug in 1978 and was patented by the university in 1979.
Michigan State University made an agreement with Bristol-Myers Squibb to produce cisplatin, the company marketed the drug under the names Platinol® and Platinol-AQ®.
Experienced Attorneys for Complex Mesothelioma Claims
At the law firm of Wallace & Graham, P.A., we offer our clients dedicated representation in all aspects of mesothelioma claims. From our offices in Salisbury, North Carolina, we handle cases involving mesothelioma and a variety of other asbestos-related conditions for victims.
In addition to providing superior legal representation, we also strive to be a resource for people seeking information about mesothelioma, its treatment and other issues. The links below provide additional information about cisplatin that you may find beneficial.
Always consult with your doctor and/or oncologist before beginning any chemotherapy treatment regimen.
Speak to a North Carolina Mesothelioma Litigation Lawyer Today
If you or a loved one has been diagnosed with mesothelioma, speak to an attorney about your legal options. Call us at 1-888-698-9975 or contact us online for a free case evaluation. Our experienced and skilled mesothelioma lawyers will explain your rights and fight for you.